Anish Badjatiya1, Peter Merrill2, John B Buse3, Shaun G Goodman4,5, Brian Katona6, Nayyar Iqbal, Neha J Pagidipati2,7, Naveed Sattar8, Rury R Holman9, Adrian F Hernandez2,7, Robert J Mentz2,7, Manesh R Patel2,7, W Schuyler Jones2,7. 1. Department of Internal Medicine (A.B.), Duke University School of Medicine, Durham, NC. 2. Duke Clinical Research Institute (P.M., N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.), Duke University School of Medicine, Durham, NC. 3. Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill (J.B.B.). 4. Canadian VIGOUR Centre, University of Alberta, Edmonton, Canada (S.G.G.). 5. St. Michael's Hospital, Department of Medicine, University of Toronto, ON, Canada (S.G.G.). 6. AstraZeneca Research and Development, Gaithersburg, MD (B.K.). 7. Division of Cardiology, Duke University School of Medicine, Durham, NC (N.J.P., A.F.H., R.J.M., M.R.P. W.S.J.). 8. Institute of Cardiovascular and Medical Sciences, University of Glasgow (N.S.). 9. Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, United Kingdom (R.R.H.).
Abstract
BACKGROUND: Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater incidence of diabetes mellitus and risk for LEA, prompting this investigation of clinical outcomes in patients with diabetes mellitus and PAD in the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering). METHODS: EXSCEL evaluated the effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placebo on the rates of the primary composite MACE end point (cardiovascular death, myocardial infarction, or stroke) among patients with type 2 diabetes mellitus. In this post hoc analysis, we assessed the association of baseline PAD with rates of MACE, LEA, and the effects of exenatide versus placebo in patients with and without PAD. RESULTS: EXSCEL included 2800 patients with PAD (19% of the trial population). These individuals had higher unadjusted and adjusted rates of MACE compared with patients without PAD (13.6% versus 11.4%, respectively) as well as a higher adjusted hazard ratio (adjusted hazard ratio, 1.13 [95% CI, 1.00-1.27]; P=0.047). Patients with PAD had higher all-cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20-1.60]; P<0.001) and more frequent LEA (adjusted hazard ratio 5.48 [95% CI, 4.16-7.22]; P<0.001). Patients treated with exenatide or placebo had similar rates of MACE and LEA, regardless of PAD status. CONCLUSIONS: EXSCEL participants with PAD had higher rates of all-cause mortality and LEA compared with those without PAD. There were no differences in MACE or LEA rates with exenatide versus placebo. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT01144338.
RCT Entities:
BACKGROUND: Recent trials have identified anti-diabetes mellitus agents that lower major adverse cardiovascular event (MACE) rates, although some increase rates of lower-extremity amputation (LEA). Patients with peripheral artery disease (PAD) have greater incidence of diabetes mellitus and risk for LEA, prompting this investigation of clinical outcomes in patients with diabetes mellitus and PAD in the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering). METHODS: EXSCEL evaluated the effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor agonist) versus placebo on the rates of the primary composite MACE end point (cardiovascular death, myocardial infarction, or stroke) among patients with type 2 diabetes mellitus. In this post hoc analysis, we assessed the association of baseline PAD with rates of MACE, LEA, and the effects of exenatide versus placebo in patients with and without PAD. RESULTS: EXSCEL included 2800 patients with PAD (19% of the trial population). These individuals had higher unadjusted and adjusted rates of MACE compared with patients without PAD (13.6% versus 11.4%, respectively) as well as a higher adjusted hazard ratio (adjusted hazard ratio, 1.13 [95% CI, 1.00-1.27]; P=0.047). Patients with PAD had higher all-cause mortality (adjusted hazard ratio 1.38 [95% CI, 1.20-1.60]; P<0.001) and more frequent LEA (adjusted hazard ratio 5.48 [95% CI, 4.16-7.22]; P<0.001). Patients treated with exenatide or placebo had similar rates of MACE and LEA, regardless of PAD status. CONCLUSIONS: EXSCEL participants with PAD had higher rates of all-cause mortality and LEA compared with those without PAD. There were no differences in MACE or LEA rates with exenatide versus placebo. Clinical Trial Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT01144338.
Authors: Marc D Samsky; Robert J Mentz; Amanda Stebbins; Yuliya Lokhnygina; Aaron W Aday; Neha J Pagidipati; W Schuyler Jones; Brian G Katona; Manesh R Patel; Rury R Holman; Adrian F Hernandez; Jorge Antonio Gutierrez Journal: Atherosclerosis Date: 2021-11-01 Impact factor: 5.162
Authors: Kevin Kris Warnakula Olesen; Christine Gyldenkerne; Troels Thim; Reimar Wernich Thomsen; Michael Maeng Journal: BMJ Open Diabetes Res Care Date: 2021-01
Authors: E Hope Weissler; Robert M Clare; Yuliya Lokhnygina; John B Buse; Shaun G Goodman; Brian Katona; Nayyar Iqbal; Neha J Pagidipati; Naveed Sattar; Rury R Holman; Adrian F Hernandez; Robert J Mentz; Manesh R Patel; W Schuyler Jones Journal: Diabet Med Date: 2021-03-18 Impact factor: 4.213
Authors: Subodh Verma; Mohammed Al-Omran; Lawrence A Leiter; C David Mazer; Søren Rasmussen; Hans A Saevereid; Maria Sejersten Ripa; Marc P Bonaca Journal: Diabetes Obes Metab Date: 2022-04-11 Impact factor: 6.408